Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT06723015
PHASE2

Tau PET Outcomes With Anti-amyloid Immunotherapies

Sponsor: Mayo Clinic

View on ClinicalTrials.gov

Summary

This is an imaging study of patients with mild Alzheimer's disease receiving amyloid-targeting therapy and under the care of neurologists at Mayo Clinic in Rochester, MN.

Official title: Study of Tau PET Outcomes in Patients Receiving Anti-amyloid Immunotherapies

Key Details

Gender

All

Age Range

50 Years - 90 Years

Study Type

INTERVENTIONAL

Enrollment

135

Start Date

2025-11-04

Completion Date

2028-08

Last Updated

2025-11-18

Healthy Volunteers

No

Interventions

DRUG

18F-AV-1451

Subjects will receive two Tau PET (18F--AV-1451) brain scans with approximately 10 mCi (370 MBq) (+/- 10%mCi) of 18F-AV-1451. Images will be collected for a 20-minute acquisition between 80-100 minutes after injection. Tau PET scans will occur at baseline and 12-18 months after completing anti-amyloid immunotherapy treatment..

Locations (1)

Mayo Clinic

Rochester, Minnesota, United States